company background image
ABLI

Abliva OM:ABLI Stock Report

Last Price

kr0.28

Market Cap

kr291.5m

7D

5.1%

1Y

-61.0%

Updated

10 Aug, 2022

Data

Company Financials +
ABLI fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

ABLI Stock Overview

Abliva AB (publ) develops medicines for the treatment of primary mitochondrial diseases.

Abliva Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Abliva
Historical stock prices
Current Share Pricekr0.28
52 Week Highkr0.76
52 Week Lowkr0.22
Beta0.81
1 Month Change6.15%
3 Month Change-26.98%
1 Year Change-61.04%
3 Year Change-85.41%
5 Year Change-94.03%
Change since IPO-95.75%

Recent News & Updates

Shareholder Returns

ABLISE BiotechsSE Market
7D5.1%-1.9%-0.8%
1Y-61.0%-22.8%-23.9%

Return vs Industry: ABLI underperformed the Swedish Biotechs industry which returned -22.8% over the past year.

Return vs Market: ABLI underperformed the Swedish Market which returned -23.9% over the past year.

Price Volatility

Is ABLI's price volatile compared to industry and market?
ABLI volatility
ABLI Average Weekly Movement10.1%
Biotechs Industry Average Movement9.7%
Market Average Movement7.3%
10% most volatile stocks in SE Market12.7%
10% least volatile stocks in SE Market4.6%

Stable Share Price: ABLI is more volatile than 75% of Swedish stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: ABLI's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Swedish stocks.

About the Company

FoundedEmployeesCEOWebsite
20008Ellen Donnellyhttps://abliva.com

Abliva AB (publ) develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children’s Hospital of Philadelphia, and Oroboros Instruments.

Abliva Fundamentals Summary

How do Abliva's earnings and revenue compare to its market cap?
ABLI fundamental statistics
Market Capkr291.54m
Earnings (TTM)-kr124.06m
Revenue (TTM)kr151.00k

1,971x

P/S Ratio

-2.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ABLI income statement (TTM)
Revenuekr151.00k
Cost of Revenuekr105.51m
Gross Profit-kr105.35m
Other Expenseskr18.71m
Earnings-kr124.06m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

Aug 19, 2022

Earnings per share (EPS)-0.12
Gross Margin-69,770.86%
Net Profit Margin-82,161.59%
Debt/Equity Ratio0.0%

How did ABLI perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is ABLI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ABLI?

Other financial metrics that can be useful for relative valuation.

ABLI key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1772.6x
Enterprise Value/EBITDA-2.3x
PEG Ration/a

Price to Book Ratio vs Peers

How does ABLI's PB Ratio compare to its peers?

ABLI PB Ratio vs Peers
The above table shows the PB ratio for ABLI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average2.3x
LIDDS LIDDS
6.3xn/akr242.8m
SANION Saniona
1.7xn/akr274.5m
VIVE Vivesto
0.7xn/akr428.6m
IMMU Mendus
0.8x-7.4%kr490.5m
ABLI Abliva
14.5xn/akr291.5m

Price-To-Book vs Peers: ABLI is expensive based on its Price-To-Book Ratio (14.5x) compared to the peer average (2.3x).


Price to Earnings Ratio vs Industry

How does ABLI's PE Ratio compare vs other companies in the SE Biotechs Industry?

Price-To-Book vs Industry: ABLI is expensive based on its Price-To-Book Ratio (14.5x) compared to the Swedish Biotechs industry average (2.3x)


Price to Book Ratio vs Fair Ratio

What is ABLI's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ABLI PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio14.5x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate ABLI's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of ABLI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ABLI's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ABLI's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is Abliva forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


33.4%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Abliva has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Examine Abliva's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • Abliva competitive advantages and company strategy can generally be found in its financial reports archived here.

Past Performance

How has Abliva performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-8.1%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ABLI is currently unprofitable.

Growing Profit Margin: ABLI is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ABLI is unprofitable, and losses have increased over the past 5 years at a rate of 8.1% per year.

Accelerating Growth: Unable to compare ABLI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ABLI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.2%).


Return on Equity

High ROE: ABLI has a negative Return on Equity (-616.83%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Abliva's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: ABLI's short term assets (SEK27.3M) exceed its short term liabilities (SEK17.3M).

Long Term Liabilities: ABLI's short term assets (SEK27.3M) exceed its long term liabilities (SEK24.2M).


Debt to Equity History and Analysis

Debt Level: ABLI is debt free.

Reducing Debt: ABLI has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ABLI has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: ABLI has less than a year of cash runway if free cash flow continues to reduce at historical rates of 4% each year


Discover healthy companies

Dividend

What is Abliva current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate ABLI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ABLI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ABLI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ABLI's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ABLI has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

6.6yrs

Average management tenure


CEO

Ellen Donnelly (48 yo)

1.5yrs

Tenure

kr3,838,994

Compensation

Dr. Ellen K. Donnelly, Ph D has been Chief Executive Officer at Abliva AB (publ) since February 03, 2021. She serves as Independent Director at Modus Therapeutics Holding Ab since 2020.Dr. Donnelly has be...


CEO Compensation Analysis

Compensation vs Market: Ellen's total compensation ($USD382.79K) is above average for companies of similar size in the Swedish market ($USD246.34K).

Compensation vs Earnings: Insufficient data to compare Ellen's compensation with company performance.


Leadership Team

Experienced Management: ABLI's management team is seasoned and experienced (6.6 years average tenure).


Board Members

Experienced Board: ABLI's board of directors are considered experienced (5.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: ABLI insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 162.1%.


Top Shareholders

Company Information

Abliva AB (publ)'s employee growth, exchange listings and data sources


Key Information

  • Name: Abliva AB (publ)
  • Ticker: ABLI
  • Exchange: OM
  • Founded: 2000
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: kr291.539m
  • Shares outstanding: 1.06b
  • Website: https://abliva.com

Number of Employees


Location

  • Abliva AB (publ)
  • Medicon Village
  • Lund
  • Skåne County
  • 223 81
  • Sweden

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/10 00:00
End of Day Share Price2022/08/10 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.